ATE383871T1 - Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene - Google Patents

Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene

Info

Publication number
ATE383871T1
ATE383871T1 AT01921281T AT01921281T ATE383871T1 AT E383871 T1 ATE383871 T1 AT E383871T1 AT 01921281 T AT01921281 T AT 01921281T AT 01921281 T AT01921281 T AT 01921281T AT E383871 T1 ATE383871 T1 AT E383871T1
Authority
AT
Austria
Prior art keywords
opri
pseudomonas
heterologue
antigens
lipoprotein
Prior art date
Application number
AT01921281T
Other languages
English (en)
Inventor
Hilde Revets
Pierre Cornelis
Baetselier Patrick De
Original Assignee
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE383871T1 publication Critical patent/ATE383871T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/824—Bacterial vaccine for ovine species, e.g. sheep
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01921281T 2000-02-18 2001-02-13 Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene ATE383871T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00200589 2000-02-18

Publications (1)

Publication Number Publication Date
ATE383871T1 true ATE383871T1 (de) 2008-02-15

Family

ID=8171051

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01921281T ATE383871T1 (de) 2000-02-18 2001-02-13 Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene

Country Status (7)

Country Link
US (1) US6936263B2 (de)
EP (1) EP1255562B1 (de)
AT (1) ATE383871T1 (de)
AU (2) AU2001248314B2 (de)
CA (1) CA2400495A1 (de)
DE (1) DE60132427D1 (de)
WO (1) WO2001060404A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001248314B2 (en) * 2000-02-18 2004-08-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
WO2003055527A2 (en) * 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
US20100129385A1 (en) * 2005-02-08 2010-05-27 Jackson David C Immunogenic molecules
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US7833776B2 (en) 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
WO2010148496A1 (en) * 2009-06-22 2010-12-29 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
CN113150171B (zh) * 2021-04-25 2023-05-16 中国农业科学院兰州兽医研究所 含分子内佐剂的非洲猪瘟病毒重组蛋白、表达载体及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829616C2 (de) * 1988-09-01 1996-08-29 Behringwerke Ag Lipoprotein I (OMPI) von Pseudomonas aeruginosa
FR2708622B1 (fr) * 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0717106B1 (de) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenes Hybridprotein OprF-Oprl erhältlich aus Membranproteinen von Pseudomonas aeruginosa
WO1997000067A1 (en) * 1995-06-15 1997-01-03 University Of Victoria Innovation And Development Mycobacterium tuberculosis dna sequences encoding immunostimulatory peptides
US6607731B1 (en) * 1995-09-22 2003-08-19 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6638517B2 (en) * 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6613337B1 (en) * 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6537552B1 (en) * 1999-10-19 2003-03-25 Iowa State University Research Foundation Vaccine adjuvant
AU2001248314B2 (en) * 2000-02-18 2004-08-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens

Also Published As

Publication number Publication date
EP1255562B1 (de) 2008-01-16
US20030059439A1 (en) 2003-03-27
AU4831401A (en) 2001-08-27
EP1255562A2 (de) 2002-11-13
WO2001060404A2 (en) 2001-08-23
AU2001248314B2 (en) 2004-08-19
WO2001060404A3 (en) 2002-01-10
DE60132427D1 (de) 2008-03-06
CA2400495A1 (en) 2001-08-23
US6936263B2 (en) 2005-08-30

Similar Documents

Publication Publication Date Title
DE60132427D1 (de) Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene
NO20023829L (no) Proteosom influensavaksine
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
FR2814958B1 (fr) Composition vaccinale
DE60238471D1 (de) Proteosom-liposaccharid-vakzine-adjuvans
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
DK0759935T3 (da) Rekombinant papillomavirus L1
TR199801722T2 (xx) Peptit imm�nojenler.
DE60117164D1 (de) Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
ATE386806T1 (de) Antigene polypeptide
HU9904549A (en) Vaccines
PT1221968E (pt) Processo de obtenção de respostas imunes celulares de proteínas
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
DK1328547T3 (da) Identifikation og modifikation af immundominante epitoper i polypeptider
CY1110430T1 (el) Πολυπεπτιδια περιεχοντα πολυμορφισμους των επαναλαμβανομενων περιοχων της περτακτινης σε bordetella pertussis, bordetella paraperussis kai bordetella bronchiseptica. χρηση αυτων σε διαγνωστικες και ανοσογονες συνθεσεις
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
WO2003089584A3 (en) Use of parapox b2l protein to modify immune responses to administered antigens
DE69420970D1 (de) Impfstoff zubereitungen
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
DE69923996D1 (de) Methode für die herstellung von gereinigtem invasinprotein und seine anwendung
WO2003050135A3 (en) Use a parapox b2l protein to modify immune responses to administered antigens
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens
ITRM20010332A1 (it) Vaccini a subunita' e procedimenti per la loro produzione.
AR037908A1 (es) Una biomasa en particulas de embrion aviar para la produccion de antigenos de virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties